Tandem Diabetes Care's stock plummeted 5.23% during intraday trading on Monday.
The decline followed analyst price target cuts from Barclays and Truist Securities. Barclays lowered its price target to $55 from $56, while Truist Securities cut its target to $31 from $35.
Despite Mizuho raising its price target to $24 from $22, the negative adjustments from other firms likely contributed to investor concerns, leading to the stock's drop.